(INDIANAPOLIS) - Indianapolis-based Eli Lilly has announced Phase III testing of an inhibitor designed to treat Alzheimer's disease.
The company says 1,500 patients in the US and 21 other countries will be studied for nearly two years.
Researchers are trying to find out if the inhibitor can slow the progression associated with Alzheimer's by blocking an enzyme that can crate a protein which is believed to eventually kill off brain cells estimates show that 6 to 8% of people over age 65 are affected by Alzheimer's disease, totaling approximately 5 million people in the United States alone.
Have a question or comment about a news story? Send it to email@example.com